Solitomab

OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Monday, November 14, 2022
Technology, Research, Nanotechnology, Clinical Trials, Stem Cells, Biotechnology, Health, Science, Oncology, Trichloroethylene, Protein engineering, Solitomab, TCE, Therapeutic index, Toxicity, Doctor of Philosophy, Society, Immunotherapy, SITC, Research and development, Pharmaceutical industry, Medical imaging, Research

OncoNano Medicine, Inc. today announced the presentations of positive preclinical data on the companys ON-BOARD pH-activatable delivery platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts.

Key Points: 
  • OncoNano Medicine, Inc. today announced the presentations of positive preclinical data on the companys ON-BOARD pH-activatable delivery platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts.
  • The data presented at SITC 2022 demonstrated the capability of the ON-BOARD platform for effective encapsulation and improvement of the therapeutic index of a variety of therapeutic payloads, including bispecific T cell engagers (TCE) and a therapeutic cytokine IL-2-Fc, using relevant animal models.
  • The ON-BOARD platform is designed to protect oncology intervention payloads systemically and release them in the acidic tumor microenvironment, minimizing systemic exposure and toxicity.
  • We look forward to developing this technology for clinical translation with these types of payload molecules in the near future.

Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Retrieved on: 
Wednesday, July 8, 2020
Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager

Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.

Key Points: 
  • Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.
  • Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.
  • Atrecas unique discovery platform complements our protein engineering capabilities and bispecific platform by providing novel, tumor-selective antibodies and targets to engage with cytotoxic T cell killing.
  • This collaboration offers both Xencor and Atreca with several opportunities to advance novel first-in-class CD3 bispecific antibodies for the potential treatment of patients with cancer.

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Retrieved on: 
Wednesday, July 8, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager, XmAb® Bispecific Fc Technology and CD3 Bispecific Antibodies, Xencor, Inc., Atreca, Inc.

Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.

Key Points: 
  • Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.
  • Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.
  • Atrecas unique discovery platform complements our protein engineering capabilities and bispecific platform by providing novel, tumor-selective antibodies and targets to engage with cytotoxic T cell killing.
  • This collaboration offers both Xencor and Atreca with several opportunities to advance novel first-in-class CD3 bispecific antibodies for the potential treatment of patients with cancer.

Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Retrieved on: 
Friday, May 15, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Medicine, Branches of biology, Immunology, Monoclonal antibodies, Immune system, Bispecific monoclonal antibody, Mesothelin, Antibody, Solitomab, Immunohistochemistry

These two tumor-targeting binding domains can bind together when there's more target present, a property called avidity, said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.

Key Points: 
  • These two tumor-targeting binding domains can bind together when there's more target present, a property called avidity, said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.
  • At AACR, we are presenting data from preclinical models showing strong, selective tumor killing from XmAb 2+1 bispecific antibody programs that target PSMA, mesothelin and ENPP3, the last of which is an underexplored tumor antigen overexpressed on renal cell carcinomas.
  • Title: XmAb30819, an XmAb 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in-vivo preclinical studies
    These posters and audio descriptions will be available to registrants of the AACR Virtual Annual Meeting at 9:00 a.m. EDT on Monday, June 22.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

Retrieved on: 
Tuesday, March 24, 2020
Medicine, Medical specialties, Clinical medicine, Monoclonal antibodies, Immunology, Immune system, Tumor, Tumor microenvironment, Cancer treatments, Chimeric antigen receptor T cell, Solitomab

The parties will utilize CytomXs Probody therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.

Key Points: 
  • The parties will utilize CytomXs Probody therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.
  • This collaboration with Astellas leverages CytomXs deep expertise in targeting multiple antibody modalities to the tumor microenvironment, said Sean McCarthy, D.
  • Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment.
  • Probody T-cell engaging bispecifics are antibody constructs capable of directing cytotoxic T-cells to tumor microenvironments, leading to cell-mediated anti-cancer activity.

Global Bispecific Antibodies for Cancer Market 2019-2023| Emerging Bispecific Antibody Generation Platforms to Boost Growth | Technavio

Retrieved on: 
Friday, May 3, 2019
Health, Oncology, Medical specialties, Monoclonal antibodies, Medicine, Immunology, Immune system, Bispecific monoclonal antibody, CD16, Antibody, Istiratumab, Solitomab

View the full release here: https://www.businesswire.com/news/home/20190503005272/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190503005272/en/
    Technavio has published a new market research report on the global bispecific antibodies for Cancer market from 2019-2023.
  • (Graphic: Business Wire)
    A key factor driving the growth of the global bispecific antibodies for cancer market is the advantages of bispecific antibodiesover monoclonal antibodies.
  • Global bispecific antibodies for cancer market: Emerging bispecific antibody generation platforms
    Bispecific antibodies are becoming one of the most promising cancer immunotherapy options, which may offer significant advantages in cancer treatment.
  • Global bispecific antibodies for cancer market: Segmentation analysis
    This market research report segments the global bispecific antibodies for cancer market by target (CD19/CD3 and CD30/CD16A) and geographic regions (North America, Europe, Asia, and ROW).

The bispecific antibodies for cancer market will register a CAGR of over 30% by 2023

Retrieved on: 
Monday, April 29, 2019
Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, Bispecific monoclonal antibody, Antibody, Solitomab, Trifunctional antibody

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period.

Key Points: 
  • The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period.
  • Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy.
  • Analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.
  • For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view our report.